Cadrenal Therapeutics CVKD
NASDAQ CVKD
$0.95 -0.02 (-2.06%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026)

Updated

Cadrenal Therapeutics (CVKD) posted Return on Equity [ROE] of -400.44% for Q2 2026, down 205.83 percentage points from -194.61% a year earlier.

Analysis

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026) Analysis & Trends

For FY2023, Cadrenal Therapeutics' Return on Equity [ROE] came in at -689.68%.

  • The Q2 2026 figure stands as the lowest quarterly Return on Equity [ROE] in data going back to Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Cadrenal Therapeutics 2.94 Mn -9.67 Mn - -400.44%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -400.44%
Jun 30, 2025 -194.61%
Sep 30, 2024 -205.50%
Jun 30, 2024 -122.48%
Mar 31, 2024 -69.82%
Dec 31, 2023 -89.88%
Sep 30, 2023 -123.09%
Jun 30, 2023 -201.27%
API Access

Cadrenal Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=CVKD&period=max&api_key=YOUR_API_KEY